Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems

被引：51

作者：

Galasko, Douglas ^{[1
]}

Golde, Todd E. ^{[2
]}

机构：

[1] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA

[2] Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA

来源：

ALZHEIMERS RESEARCH & THERAPY | 2013年 / 5卷 / 02期

基金：

美国国家卫生研究院;

关键词：

AMYLOID-BETA; CEREBROSPINAL-FLUID; RISK; ASSOCIATION; DEMENTIA; CLUSTERIN; DIAGNOSIS;

D O I：

10.1186/alzrt164

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Substances produced throughout the body are detectable in the blood, which is the most common biological fluid used in clinical testing. Biomarkers for Alzheimer's disease (AD) have long been sought in the blood, but none has become an established or validated diagnostic test. Companion reviews in Alzheimer's Research & Therapy will review specific types of biomarkers or applications; in this overview, we cover key concepts related to AD blood biomarker studies in general. Reasons for the difficulty of detecting markers of a brain-specific disorder, such as AD, in the blood are outlined; these pose conceptual challenges for blood biomarker discovery and development. Applications of blood tests in AD go beyond screening and diagnostic testing; other potential uses are risk assessment, prognostication, and evaluation of treatment target engagement, toxicity, and outcome. Opportunities and questions that may surround these different uses are discussed. A systematic approach to biomarker discovery, detection, assay development and quality control, sample collection, handling and storage, and design and analysis of clinical studies needs to be implemented at every step of discovery and translation to identify an interpretable and useful biomarker.

引用

页数：5

共 23 条

[1] A prototypical process for creating evidentiary standards for biomarkers and diagnostics [J].

Altar, C. A. ;

Amakye, D. ;

Bounos, D. ;

Bloom, J. ;

Clack, G. ;

Dean, R. ;

Devanarayan, V. ;

Fu, D. ;

Furlong, S. ;

Hinman, L. ;

Girman, C. ;

Lathia, C. ;

Lesko, L. ;

Madani, S. ;

Mayne, J. ;

Meyer, J. ;

Raunig, D. ;

Sager, P. ;

Williams, S. A. ;

Wong, P. ;

Zerba, K. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :368-371

[2] Multiplex serum biomarker assessments: technical and biostatistical issues [J].

Butterfield, Lisa H. ;

Potter, Douglas M. ;

Kirkwood, John M. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9 :173

[3] Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease [J].

Doecke, James D. ;

Laws, Simon M. ;

Faux, Noel G. ;

Wilson, William ;

Burnham, Samantha C. ;

Lam, Chiou-Peng ;

Mondal, Alinda ;

Bedo, Justin ;

Bush, Ashley I. ;

Brown, Belinda ;

De Ruyck, Karl ;

Ellis, Kathryn A. ;

Fowler, Christopher ;

Gupta, Veer B. ;

Head, Richard ;

Macaulay, S. Lance ;

Pertile, Kelly ;

Rowe, Christopher C. ;

Rembach, Alan ;

Rodrigues, Mark ;

Rumble, Rebecca ;

Szoeke, Cassandra ;

Taddei, Kevin ;

Taddei, Tania ;

Trounson, Brett ;

Ames, David ;

Masters, Colin L. ;

Martins, Ralph N. .

ARCHIVES OF NEUROLOGY, 2012, 69 (10) :1318-1325

[4] Decreased Cerebrospinal Fluid Aβ42 Correlates with Brain Atrophy in Cognitively Normal Elderly [J].

Fagan, Anne M. ;

Head, Denise ;

Shah, Aarti R. ;

Marcus, Daniel ;

Mintun, Mark ;

Morris, John C. ;

Holtzman, David M. .

ANNALS OF NEUROLOGY, 2009, 65 (02) :176-183

[5] Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease [J].

Graff-Radford, Neill R. ;

Crook, Julia E. ;

Lucas, John ;

Boeve, Bradley F. ;

Knopman, David S. ;

Ivnik, Robert J. ;

Smith, Glenn E. ;

Younkin, Linda H. ;

Petersen, Ronald C. ;

Younkin, Steven G. .

ARCHIVES OF NEUROLOGY, 2007, 64 (03) :354-362

[6] Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease [J].

Hu, William T. ;

Holtzman, David M. ;

Fagan, Anne M. ;

Shaw, Leslie M. ;

Perrin, Richard ;

Arnold, Steven E. ;

Grossman, Murray ;

Xiong, Chengjie ;

Craig-Schapiro, Rebecca ;

Clark, Christopher M. ;

Pickering, Eve ;

Kuhn, Max ;

Chen, Yu ;

Van Deerlin, Vivianna M. ;

McCluskey, Leo ;

Elman, Lauren ;

Karlawish, Jason ;

Chen-Plotkin, Alice ;

Hurtig, Howard I. ;

Siderowf, Andrew ;

Swenson, Frank ;

Lee, Virginia M-Y. ;

Morris, John C. ;

Trojanowski, John Q. ;

Soares, Holly .

NEUROLOGY, 2012, 79 (09) :897-905

[7] Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade [J].

Jack, Clifford R., Jr. ;

Knopman, David S. ;

Jagust, William J. ;

Shaw, Leslie M. ;

Aisen, Paul S. ;

Weiner, Michael W. ;

Petersen, Ronald C. ;

Trojanowski, John Q. .

LANCET NEUROLOGY, 2010, 9 (01) :119-128

[8] Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset [J].

Johnstone, Daniel ;

Milward, Elizabeth A. ;

Berretta, Regina ;

Moscato, Pablo .

PLOS ONE, 2012, 7 (04)

[9] Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline A Systematic Review and Meta-analysis [J].

Koyama, Alain ;

Okereke, Olivia I. ;

Yang, Ting ;

Blacker, Deborah ;

Selkoe, Dennis J. ;

Grodstein, Francine .

ARCHIVES OF NEUROLOGY, 2012, 69 (07) :824-831

[10] Validation of a Multiplex Assay for Simultaneous Quantification of Amyloid-β Peptide Species in Human Plasma with Utility for Measurements in Studies of Alzheimer's Disease Therapeutics [J].

Lachno, D. Richard ;

Emerson, Julie K. ;

Vanderstichele, Hugo ;

Gonzales, Celedon ;

Martenyi, Ferenc ;

Konrad, Robert J. ;

Talbot, Jayne A. ;

Lowe, Stephen L. ;

Oefinger, Paul E. ;

Dean, Robert A. .

JOURNAL OF ALZHEIMERS DISEASE, 2012, 32 (04) :905-918

← 1 2 3 →